120
Participants
Start Date
July 31, 2021
Primary Completion Date
July 31, 2022
Study Completion Date
July 31, 2022
Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live
Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Bifidobacterium, Lactobacillus, Enterococcus and Bacillus Cereus Tablets, Live (Siliankang) 3 tablets p.o. tid for 12 weeks.
Siliankang simulating tablets
Patients will be instructed to continue current antidiabetic treatment, which should be kept unchanged throughout the trial, and start treatment with Siliankang simulative tablets 3 tablets p.o. tid for 12 weeks.
Peking Union Medical College Hospital, Beijing
Collaborators (1)
First Affiliated Hospital of Harbin Medical University
OTHER
The Affiliated Hospital of Inner Mongolia Medical University
OTHER
Affiliated Hospital of Chengde Medical University
OTHER
The First Affiliated Hospital of Zhengzhou University
OTHER
Chinese Academy of Sciences
OTHER_GOV
Hangzhou Grand Biologic Pharmaceutical, Inc.
INDUSTRY
Peking Union Medical College Hospital
OTHER